Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519167 | 0.84 | BRD4 (0.49) | BRD4MAPTMMEPOLBACE | |
| SCHEMBL564528 | 0.77 | AGTR2 (0.41) | MAPTKMT2A | |
| SCHEMBL563200 | 0.75 | BRD4 (0.43) | BRD4MAPTNR1H2 | |
| SCHEMBL10239639 | 0.75 | BRD4 (0.43) | BRD4MAPTNR1H2 | |
| SCHEMBL563053 | 0.75 | LMNA (0.50) | BRD4MAPTMMEPOLBKMT2A | |
| SCHEMBL562012 | 0.75 | LMNA (0.50) | BRD4MAPTMMEPOLBKMT2A | |
| SCHEMBL5012986 | 0.74 | ACE (0.43) | BRD4MAPTMMEPOLBACE | |
| SCHEMBL11534030 | 0.73 | BRD4 (0.58) | BRD4MAPTPOLBKMT2A | |
| SCHEMBL14318604 | 0.73 | MAPT (0.40) | BRD4MAPTMMEPOLBACE | |
| SCHEMBL563665 | 0.72 | BRD4 (0.46) | BRD4MAPTPOLBACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492416-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB Biopharma SRL (BE) | 2012-02-09 | — | — | US | disclosed |
| US-8034958-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UOB Pharma, S.A. (BE) | 2011-10-11 | — | — | US | disclosed |
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | DIFFERDING EDMOND (BE) | 2005-08-04 | — | — | US | disclosed |
| US-6911461-B2 | For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse | UCB, S.A. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-20040116507-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB Biopharma SRL (BE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | BRD4 2140/4885MAPT 957/4885MME 4438/4885 |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | CYP1B1, OGDH, CYP1A2 | BRD4 2140/4885MAPT 957/4885MME 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.